GSK Wins FDA Approval For Chronic Hepatitis B Drug
FDA clears GSK Hibsago for chronic hepatitis B in adults, delivering strong functional cure rates and suppressing viral replication targets.
Share
Why It Matters
GSK just got permission to sell a new hepatitis B medicine. When a company gets a new drug approved, it can help sick people and make money.
This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Tickers in Play
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.